Roxithromycin: Effective Treatment for Bacterial Infections
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.85 | $50.74 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $76.11 $69.66 (8%) | 🛒 Add to cart |
| 120 | $0.73 | $101.48 $87.72 (14%) | 🛒 Add to cart |
| 180 | $0.70 | $152.22 $125.56 (18%) | 🛒 Add to cart |
| 270 | $0.67 | $228.33 $181.46 (21%) | 🛒 Add to cart |
| 360 | $0.66
Best per pill | $304.44 $239.08 (21%) | 🛒 Add to cart |
Synonyms
| |||
Roxithromycin is a semi-synthetic macrolide antibiotic derived from erythromycin, designed to offer broad-spectrum antibacterial activity with an improved pharmacokinetic profile. It is commonly prescribed for respiratory, skin, and soft tissue infections caused by susceptible organisms. The drug exhibits high tissue penetration, stability in acidic environments, and a convenient once- or twice-daily dosing regimen, enhancing patient compliance. Its mechanism involves inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit.
Features
- Belongs to the macrolide antibiotic class
- Available in 150 mg and 300 mg tablet formulations
- Exhibits activity against Gram-positive and some Gram-negative bacteria, as well as atypical pathogens
- Oral administration with high bioavailability (~50%)
- Long elimination half-life (approximately 12 hours)
- Metabolized primarily in the liver and excreted via bile and urine
Benefits
- Effective against common community-acquired respiratory pathogens including Streptococcus pneumoniae, Mycoplasma pneumoniae, and Chlamydophila pneumoniae
- Convenient dosing schedule supports adherence to therapy
- Generally well-tolerated with a favorable side effect profile compared to older macrolides
- Suitable for patients with penicillin allergies where macrolides are indicated
- Demonstrates good tissue penetration, particularly in lung and skin structures
- May be used in both adult and pediatric populations (where approved and appropriate)
Common use
Roxithromycin is indicated for the treatment of mild to moderate bacterial infections including:
- Upper and lower respiratory tract infections (e.g., pharyngitis, tonsillitis, acute bronchitis, community-acquired pneumonia)
- Skin and soft tissue infections such as erysipelas, impetigo, and secondary infected dermatoses
- Genitourinary infections caused by susceptible organisms (e.g., non-gonococcal urethritis, cervicitis)
- Dental infections including periodontitis and pericoronitis
- Prophylaxis against bacterial endocarditis in high-risk patients undergoing dental procedures (where guidelines support macrolide use)
Dosage and direction
Adults: The usual dose is 300 mg daily, either as a single dose or in two divided doses of 150 mg every 12 hours. For severe infections, 300 mg twice daily may be prescribed.
Children: Dosage is based on body weight—typically 2.5–5 mg/kg twice daily. Maximum daily dose should not exceed 10 mg/kg.
Administration should occur before meals for optimal absorption. The typical treatment duration ranges from 5 to 10 days, depending on infection type and severity. Complete the full course even if symptoms improve earlier.
Precautions
- Use with caution in patients with hepatic impairment; dosage adjustment may be necessary.
- Monitor for signs of superinfection or pseudomembranous colitis.
- Not recommended during pregnancy unless potential benefits outweigh risks (Category B).
- Exercise caution in breastfeeding women; roxithromycin is excreted in breast milk.
- May prolong QT interval; avoid in patients with known arrhythmias or those taking other QT-prolonging drugs.
- Use cautiously in elderly patients due to potential for decreased hepatic or renal function.
Contraindications
- Hypersensitivity to roxithromycin, other macrolides, or any component of the formulation.
- Concurrent use with ergot derivatives, cisapride, pimozide, or terfenadine due to risk of serious cardiac events.
- Severe hepatic impairment.
- History of hepatitis or jaundice associated with previous macrolide use.
Possible side effect
Common (≥1/100):
- Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
- Headache, dizziness
- Mild skin reactions (rash, pruritus)
Uncommon (≥1/1000):
- Alterations in taste
- Transient increases in liver enzymes
- Oral or vaginal candidiasis
Rare (<1/1000):
- Pseudomembranous colitis
- Hepatitis, jaundice
- QT prolongation, ventricular arrhythmias
- Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome)
- Hearing loss (usually reversible)
Drug interaction
- Antacids/H2 blockers/PPIs: Reduced absorption; administer roxithromycin at least 2 hours before these agents.
- CYP3A4 substrates: May increase levels of drugs metabolized by this enzyme (e.g., simvastatin, midazolam, sildenafil).
- Warfarin: Potential increased anticoagulant effect; monitor INR.
- Cyclosporine, tacrolimus: Increased plasma concentrations; monitor levels and renal function.
- Oral contraceptives: Possible reduced efficacy; advise backup contraception.
- Theophylline: Slight increase in theophylline levels possible.
- Digoxin: Increased digoxin bioavailability; monitor serum levels.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to catch up. Resume the regular dosing schedule. Consistent timing helps maintain effective antibiotic concentrations.
Overdose
Symptoms may include severe nausea, vomiting, diarrhea, and transient hearing loss. Management is supportive; gastric lavage may be considered if ingestion was recent. There is no specific antidote. Hemodialysis is not effective due to high protein binding. Monitor ECG for QT prolongation and provide symptomatic care.
Storage
Store at room temperature (15–30°C) in a dry place, protected from light. Keep in the original container. Do not use after the expiration date. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosage recommendations. Do not self-medicate or share antibiotics with others.
Reviews
Clinical studies and post-marketing surveillance indicate roxithromycin is effective and well-tolerated. In a meta-analysis of respiratory infections, clinical cure rates exceeded 85%. Patients often report convenience of dosing and low incidence of gastrointestinal side effects compared to erythromycin. However, emerging bacterial resistance underscores the importance of appropriate use per local guidelines.